ERISEris Lifesciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ERIS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 200.0% YoY
- • ROE: 18.1%
- • Debt/Equity: 0.61
- • RSI: 55
- • MACD: bullish
- • Price vs EMA21: above
Bull case
- • Profit growth: 200.0% YoY
- • ROE: 18.1%
- • Debt/Equity: 0.61
- • RSI: 55
Bear case
- • Revenue growth: 7.1% YoY
- • Dividend yield: 0.57%
- • Price vs SMA50: below
- • Price vs SMA200: below
Key risks
- • Revenue growth: 7.1% YoY
- • Dividend yield: 0.57%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹32.14). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.